Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Feasibility of Ceftolozane/Tazobactam Continuous Infusion for Exacerbations of Cystic Fibrosis and Bronchiectasis Treated in an Outpatient Parenteral Antibiotic Therapy (OPAT) Setting

NCT06035055 is registered in ClinicalTrials.gov with Sunshine Coast Hospital and Health Service as lead sponsor.

NCT NCT06035055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06035055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Feasibility of Ceftolozane/Tazobactam Continuous Infusion for Exacerbations of Cystic Fibrosis and Bronchiectasis Treated in an Outpatient Parenteral Antibiotic Therapy (OPAT) Setting
Lead sponsor
Sunshine Coast Hospital and Health Service
Phase
Phase 4
Overall status
Unknown status
Start date
October 31, 2023
Completion date
January 31, 2024
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis, burkholderia cepacia infection, cystic fibrosis, pseudomonas aeruginosa